Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease
Identifieur interne : 000B32 ( PascalFrancis/Corpus ); précédent : 000B31; suivant : 000B33Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease
Auteurs : Michael Iskedjian ; Thomas R. EinarsonSource :
- PharmacoEconomics : (Auckland) [ 1170-7690 ] ; 2003.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 03-0206081 INIST |
|---|---|
| ET : | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
| AU : | ISKEDJIAN (Michael); EINARSON (Thomas R.) |
| AF : | Pharmldeas Research & Consulting Inc./Oakville, Ontario/Canada (1 aut., 2 aut.); Faculty of Pharmacy, University of Toronto/Toronto, Ontario/Canada (2 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | PharmacoEconomics : (Auckland); ISSN 1170-7690; Nouvelle-Zélande; Da. 2003; Vol. 21; No. 2; Pp. 115-127; Bibl. 25 ref. |
| LA : | Anglais |
| EA : | Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia. |
| CC : | 002B02B06 |
| FD : | Ropinirole; Lévodopa; Antiparkinsonien; Parkinson maladie; Chimiothérapie; Traitement; Homme; Economie santé; Analyse coût; Etude comparative; Agoniste; Récepteur dopaminergique D2; Stimulant dopaminergique; Analyse coût efficacité |
| FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
| ED : | Ropinirole; Levodopa; Antiparkinson agent; Parkinson disease; Chemotherapy; Treatment; Human; Health economy; Cost analysis; Comparative study; Agonist; D2 Dopamine receptor; Dopamine agonist; Cost efficiency analysis |
| EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
| SD : | Ropinirol; Levodopa; Antiparkinsoniano; Parkinson enfermedad; Quimioterapia; Tratamiento; Hombre; Economía salud; Análisis costo; Estudio comparativo; Agonista; Receptor dopaminérgico D2; Estimulante dopaminérgico; Análisis costo eficacia |
| LO : | INIST-26124.354000104169990040 |
| ID : | 03-0206081 |
Links to Exploration step
Pascal:03-0206081Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title><author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name><affiliation><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1><s2>Oakville, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name><affiliation><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1><s2>Oakville, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0206081</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 03-0206081 INIST</idno><idno type="RBID">Pascal:03-0206081</idno><idno type="wicri:Area/PascalFrancis/Corpus">000B32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title><author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name><affiliation><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1><s2>Oakville, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name><affiliation><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1><s2>Oakville, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">PharmacoEconomics : (Auckland)</title><title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title><idno type="ISSN">1170-7690</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">PharmacoEconomics : (Auckland)</title><title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title><idno type="ISSN">1170-7690</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Comparative study</term><term>Cost analysis</term><term>Cost efficiency analysis</term><term>D2 Dopamine receptor</term><term>Dopamine agonist</term><term>Health economy</term><term>Human</term><term>Levodopa</term><term>Parkinson disease</term><term>Ropinirole</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ropinirole</term><term>Lévodopa</term><term>Antiparkinsonien</term><term>Parkinson maladie</term><term>Chimiothérapie</term><term>Traitement</term><term>Homme</term><term>Economie santé</term><term>Analyse coût</term><term>Etude comparative</term><term>Agoniste</term><term>Récepteur dopaminergique D2</term><term>Stimulant dopaminergique</term><term>Analyse coût efficacité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1170-7690</s0></fA01><fA03 i2="1"><s0>PharmacoEconomics : (Auckl. )</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</s1></fA08><fA11 i1="01" i2="1"><s1>ISKEDJIAN (Michael)</s1></fA11><fA11 i1="02" i2="1"><s1>EINARSON (Thomas R.)</s1></fA11><fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1><s2>Oakville, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ></fA14><fA20><s1>115-127</s1></fA20><fA21><s1>2003</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26124</s2><s5>354000104169990040</s5></fA43><fA44><s0>0000</s0><s1>© 2003 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>25 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>03-0206081</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>PharmacoEconomics : (Auckland)</s0></fA64><fA66 i1="01"><s0>NZL</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02B06</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Ropinirole</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Ropinirole</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Ropinirol</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Economie santé</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Health economy</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Economía salud</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Analyse coût</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Cost analysis</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Análisis costo</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Etude comparative</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Comparative study</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>16</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Agoniste</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Agonist</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Agonista</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0><s5>18</s5><s6>«D2» Dopamine receptor</s6></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0><s5>18</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Dopamine agonist</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0><s5>19</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Analyse coût efficacité</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Cost efficiency analysis</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Análisis costo eficacia</s0><s5>20</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>61</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>61</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>61</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>62</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>62</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>62</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>63</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>63</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>63</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>64</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>64</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>64</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>65</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>65</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>65</s5></fC07><fN21><s1>125</s1></fN21><fN82><s1>PSI</s1></fN82></pA></standard><server><NO>PASCAL 03-0206081 INIST</NO><ET>Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</ET><AU>ISKEDJIAN (Michael); EINARSON (Thomas R.)</AU><AF>Pharmldeas Research & Consulting Inc./Oakville, Ontario/Canada (1 aut., 2 aut.); Faculty of Pharmacy, University of Toronto/Toronto, Ontario/Canada (2 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>PharmacoEconomics : (Auckland); ISSN 1170-7690; Nouvelle-Zélande; Da. 2003; Vol. 21; No. 2; Pp. 115-127; Bibl. 25 ref.</SO><LA>Anglais</LA><EA>Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.</EA><CC>002B02B06</CC><FD>Ropinirole; Lévodopa; Antiparkinsonien; Parkinson maladie; Chimiothérapie; Traitement; Homme; Economie santé; Analyse coût; Etude comparative; Agoniste; Récepteur dopaminergique D2; Stimulant dopaminergique; Analyse coût efficacité</FD><FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG><ED>Ropinirole; Levodopa; Antiparkinson agent; Parkinson disease; Chemotherapy; Treatment; Human; Health economy; Cost analysis; Comparative study; Agonist; D2 Dopamine receptor; Dopamine agonist; Cost efficiency analysis</ED><EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG><SD>Ropinirol; Levodopa; Antiparkinsoniano; Parkinson enfermedad; Quimioterapia; Tratamiento; Hombre; Economía salud; Análisis costo; Estudio comparativo; Agonista; Receptor dopaminérgico D2; Estimulante dopaminérgico; Análisis costo eficacia</SD><LO>INIST-26124.354000104169990040</LO><ID>03-0206081</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:03-0206081
|texte= Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |